Gadobutrol
Hepatic Cell Carcinoma
Massachusetts General HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Hepatic Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Afp Specific T Cell Receptor T Cells Shanghai Ruiliyuan Biotechnology Co., Ltd. | Phase 1 | CC |
HepaSphere Microspheres Assiut University | Early Phase 1 | C |
Dotarem Massachusetts General Hospital | D |
Same molecule, other indications
Gadobutrol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →